CONTENTS

Section 1: Psoriasis and Related Conditions

1. Adalimumab with Methotrexate versus Adalimumab Monotherapy in Psoriasis: First-year Results of a Single-blind Randomized Controlled Trial 1
2. Comparison between Adalimumab Introduction and Methotrexate Dose Escalation in Patients with Inadequately Controlled Psoriatic Arthritis (CONTROL): A Randomized, Open-label, Two-part, Phase 4 Study 2
3. Anxiety and Depression Association in Patients with Pediatric Psoriasis 4
4. Global Prevalence of Metabolic Syndrome in Patients with Psoriasis in the Past Two Decades: Current Evidence 5
5. Most Patients with Psoriasis Satisfied with Remote Consultations 7
6. Psoriasis and COVID-19: A Bidirectional Mendelian Randomization Study 8
7. Persistence and Effectiveness of the IL-12/23 Pathway Inhibitor Ustekinumab or Tumour Necrosis Factor Inhibitor Treatment in Patients with Psoriatic Arthritis: 1-year Results from the Real-world PsABio Study 10
8. Probiotics Supplementation Improves Quality of Life, Clinical Symptoms, and Inflammatory Status in Patients with Psoriasis 12
9. Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-world Survey in the USA and Europe 13
10. Prospective Cohort Study of Psoriatic Arthritis Risk in Patients with Psoriasis in a Real-world Psoriasis Registry 14
11. Psoriasis Adverse Events and Associated Medications as Reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021 15
12. Treatment Refractory and Super-responders in Psoriasis Biologic Agent Treatment 17
13. Impact of Fixed-dose Combination Cal/BD Foam on the Work Productivity of Patients with Psoriasis: Results from the 52-week Randomized, Double-blind, PSO-LONG Trial 19
14. Combination Therapy: A Viable Therapeutic Option for Secukinumab Secondary Failure 20
15. Drug Survival Study Looks at What Lasts Longest in RA, axSpA, PsA, and Psoriasis 22

16. Improved Plaque Psoriasis Symptoms and Satisfaction with Brodalumab Therapy Reported 23

17. Brodalumab Promising for Plaque Psoriasis 25

18. Association of Cardiac Biomarkers with Cardiovascular Outcomes in Patients with Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study 27

19. Cardiac Troponin I Level Linked to Atherosclerosis in Psoriatic Disease 28

20. New Two-year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate-to-Severe Plaque Psoriasis 30

21. Update on US FDA Review of Biologics License Application for Bimekizumab 31

22. Efficacy of Risankizumab Versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study 32

23. Patients with Psoriasis and Discrimination by Gut Microbiota 34

24. Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-world Evidence 35

25. Assessing Psoriasis Severity: Psychometric Validation of Overall Physician Global Assessment 37

26. How do Dermatologists' Personal Models Inform a Patient-centered Approach to Management: A Qualitative Study Using the Example of Prescribing a New Treatment (Apremilast) 38

27. International eDelphi study to Reach Consensus on the Methotrexate Dosing Regimen in Patients with Psoriasis 40

28. Measuring Patient-relevant Benefits in the Treatment of Psoriasis with the Patient Benefit Index: Development and Preliminary Validation of a 10-item Short Form 42

29. A Nationwide Population-based Cohort Study of the Incidence of Severe and Rare Infections Among Adults with Psoriasis in Denmark 43

30. Alcohol Consumption and Smoking in Relation to Psoriasis: A Mendelian Randomization Study 44

31. Disease Burden, Symptoms, and Use of Analgesics in Patients with Psoriasis with or without Psoriatic Arthritis: A Cross-sectional Study 46

32. Apremilast may Improve Scalp Psoriasis, Itch, and Quality of Life in Patients with Psoriasis 47

33. Differences in Face-to-face Time Spent with a Dermatologist among Patients with Psoriasis Based on Race and Ethnicity 49

34. Efficacy and Safety of JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis 50

35. Understanding Flares in Patients with Generalized Pustular Psoriasis Documented in US Electronic Health Records 51

36. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021 52

37. Incidence and Prevalence of Psoriasis in Multiethnic Johor Bahru, Malaysia: A Population-based Cohort Study Using Electronic Health Data Routinely Captured in the Teleprimary Care (TPC®) Clinical Information System from 2010 to 2020: Classification: Epidemiology 53

38. Long-term Efficacy and Safety of up to 108 Weeks of Ixekizumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial 55

39. Biologic Initiation Rates in Systemic-naive Psoriasis Patients after First-line Apremilast versus Methotrexate Use 56

40. Onset of Plaque Psoriasis Treatment Responses with Anti-IL-17/IL-23 Biologic Therapies 57

41. Secukinumab Treatment Demonstrated High Drug Survival and Sustained Effectiveness in Patients with Severe Chronic Plaque Psoriasis: 21-month Analysis in Australian Routine Clinical Practice (SUSTAIN Study) 58

42. Systemic Glucocorticoid Use and the Occurrence of Flares in Psoriatic Arthritis and Psoriasis: A Systematic Review 60

43. Transition of Topical Therapy Formulation in Psoriasis Insights from a Canadian Practice Reflective 61

44. Unmet Needs in Psoriasis Patients 62

45. Validation of the Physician's Global Assessment of Fingernail Psoriasis by Rheumatologists Treating Psoriatic Arthritis 63

46. A Practical Guide for Assessment of Skin Burden in Patients with Psoriatic Arthritis 64

47. Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis 65

48. Brodalumab in Plaque Psoriasis: Real-world Data on Effectiveness, Safety and Clinical Predictive Factors of Initial Response and Drug Survival over a Period of 104 Weeks 67

49. One-year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial 69

50. The Impact of Psoriasis on the Clinical Characteristics, Disease Burden and Treatment Patterns of Peripheral Spondyloarthritis 70

51. Guselkumab Provides Sustained Domain-specific and Comprehensive Efficacy Using Composite Indices in Patients with Active Psoriatic Arthritis 71

52. Recognizing Psoriasis in Children and Adolescents: The DIPSOC Study 72

53. Decision-making Factors for the Long-term Topical Treatment of Mild-to-Moderate Plaque Psoriasis: TEPPSO, A Case-vignette Study on Clinical Practice 73

Section 2: Eczemas

1. Efficacy and Safety of Abrocitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-blind, Multicentre Phase 3 Trial 75

2. Intrinsic Atopic Dermatitis and Extrinsic Atopic Dermatitis: Similarities and Differences 76

3. Contact Allergy to Antifungals: Results of a 12-year Retrospective Study 78

4. Association between Atopic Dermatitis and Hypertension: A Systematic Review and Meta-analysis 79

5. Atopic Dermatitis and Risk of Autoimmune Conditions: Population-based Cohort Study 80

6. Atopic Dermatitis and Risk of Major Neuropsychiatric Disorders in Children: A Population-based Cohort Study 82

7. Ruxolitinib Cream Promising for Maximum Use in Atopic Dermatitis 83

8. A Maximum-use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis 84

9. Systemic Therapy for Atopic Dermatitis in Older Adults and Adults with Comorbidities: A Scoping Review and International Eczema Council Survey 86

10. Maternal Antenatal Vitamin D Supplementation and Offspring Risk of Atopic Eczema in the First 4 years of Life: Evidence from a Randomized Controlled Trial 87

11. Phase 2 Randomized Clinical Trial of Astegolimab in Patients with Moderate-to-Severe Atopic Dermatitis 89

12. The Multidimensional Burden of Atopic Dermatitis among Adults 90

13. Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis 91

14. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis 92

15. Long-term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results through Week 52 from a Phase III Open-label Extension Trial (LIBERTY AD PED-OLE) 94

16. Dupilumab Improves Clinical Scores in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A real-world, Single-center Study 95

17. A Randomized, Observer-blind, Vehicle-control, Multi-center Clinical Investigation for Assessing the Efficacy and Tolerability of a 1% Ectoine and Hyaluronic Acid 0.1%-containing Medical Device in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis 97

18. Efficacy and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: Analysis of Follow-up Data from the Measure Up 1 and Measure Up 2 Randomized Clinical Trials 98

19. Comorbidities of Keloid and Hypertrophic Scars among Participants in UK Biobank 100

20. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-analysis 102

21. Outcomes of COVID-19 and Vaccination in Patients with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab 103

22. Parental Atopy and Risk of Atopic Dermatitis in the First Two Years of Life in the BASELINE Birth Cohort Study 105

23. Clinicophotobiological Characterization of Photoaggravated Atopic Dermatitis 106

24. Ruxolitinib Cream Quickly Addresses Itch in Atopic Dermatitis 108

25. Long-term 2-year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial 109

26. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis over a 32-week Period: An ECZTRA 3 Post Hoc Analysis 111

27. Characterization of Acne Associated with Upadacitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Integrated Analysis of 3 Phase 3 Randomized, Double-blind, Placebo-controlled Trials 113

Section 3: Urticaria

1. Sex Differences in the Efficacy of Omalizumab in the Treatment of Chronic Spontaneous Urticaria 115

2. The Common Triggers of Urticaria in Children Admitted to the Pediatric Emergency Room 116

Section 4: Hidradenitis Suppurativa

1. The Incidence and Risk of Respiratory Tract Infections in Patients Using Biologics for Hidradenitis Suppurativa: A Systematic Review and Meta-analysis 118
2. COVID-19 Vaccination Associated with Chronic Dermatoses Exacerbations 119
3. A Systematic Review and Meta-analysis of Sexual Dysfunction in Patients with Hidradenitis Suppurativa 121
4. Comorbid Diseases of Hidradenitis Suppurativa 122
5. Role of IL-36 Cytokines in Psoriasis and Other Inflammatory Skin Conditions 123
6. Infliximab in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis 124
7. Itch in Hidradenitis Suppurativa/Acne Inversa: A Systematic Review 125
8. An Up-to-date Approach to the Management of Dissecting Cellulitis 126

Section 5: Pigmentary

1. Association between Celiac Disease and Vitiligo: A Review of the Literature 128
2. Short and Long-term Outcomes of 308-nm Laser for Pediatric Vitiligo 129
3. A Randomized, Double-blind, Split-face Study of Topical Silymarin versus 2% Hydroquinone Cream in Melasmas 130
4. Evaluation of Oral Tranexamic Acid as a Novel Treatment for Melasma with a High Benefit–Risk Ratio 131

Section 6: Acne and Related Disorders

1. The Effectiveness of Prophylactic Antibiotics and Betadine Skin Preparation on Cranial Cutaneous *Cutibacterium Acnes*—A Prospective Study 132
2. Projective Personification Approach to the Experience of People with Acne and Acne Scarring—Expressing the Unspoken 133
3. Atrophic Acne Scars and Patients' Social Functioning and Emotional Well-being 134
4. Characterization of Acne Associated with Upadacitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Integrated Analysis of 3 Phase 3 Randomized, Double-blind, Placebo-controlled Trials 136
5. Efficacy of Alpha Hydroxy Acid Combined with Intense Pulsed Light in the Treatment of Acne Vulgaris: A Meta-analysis 137
6. A Randomized, Controlled, Split-face Study of Botulinum Toxin and Broadband Light for the Treatment of Erythematotelangiectatic Rosacea 138

7. Clinical and Metagenomic Profiling of Hormonal Acne-prone Skin in Different Populations 140

8. Facial Dermatoses Induced by Face Masks: A Systematic Review and Meta-analysis of Observational Studies 141

9. Hyperhidrosis is Associated with Sleep Disturbances, Daytime Tiredness, Stress, and Depression 142

10. Immune Checkpoint Inhibitors and Adverse Events in Older Patients with Melanoma 144

11. Risk of Invasive Cutaneous Squamous Cell Carcinoma after Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial 145

12. Integrative Skincare Trial of Intense Pulsed Light Followed by the Phyto-corrective Mask, Phyto-corrective Gel, and Resveratrol BE for Decreasing Post-procedure Downtime and Improving Procedure Outcomes in Patients with Rosacea 147

13. Update: Mechanisms of Topical Retinoids in Acne 148

14. Network Meta-analysis Identifies Most Effective Acne Treatments 149

15. Oral Vitamin A for Acne Management: A Possible Substitute for Isotretinoin 151

16. Photodynamic Therapy in the Treatment of Rosacea: A Systematic Review 152

17. Patient-reported Outcome Measures for Health-related Quality of Life in Patients with Acne Vulgaris: A Systematic Review of Measure Development and Measurement Properties 153

18. Endo-radiofrequency Subcision for Acne Scars Treatment: A Case Series Study 154

19. Rosacea: Treatment Targets Based on New Physiopathology Data 155

20. Assessment of Hearing Loss in Patients with Rosacea 156

21. Familial Rosacea Prevalence Higher than Previously Estimated 157

22. Spotting Fake News: A Qualitative Review of Misinformation and Conspiracy Theories in Acne Vulgaris 158

23. Advances in Topical Management of Adolescent Facial and Truncal Acne: A Phase 3 Pooled Analysis of Safety and Efficacy of Trifarotene 0.005% Cream 160

24. A Cream Containing the Sap of Oat Plantlets and Mandarin Extract Soothes the Symptoms of Rosacea and Improves the Quality of Life of Patients 161

25. Rosacea, an Infectious Disease: Why Rosacea with Papulopustules should be considered a Demodicosis. A Narrative Review 162

26. Greater Rosacea Severity Correlates with Greater Adherence and Improvement in a Clinical Study 163

27. Tazarotene 0.045% Lotion for Females with Acne: Analysis of Two Adult Age Groups 164

28. Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris 165

Section 7: Hair Disorders

1. Association between Metabolic Syndrome and Androgenetic Alopecia 167

2. Association of Mental Health Outcomes and Lower Patient Satisfaction among Adults with Alopecia: A Cross-sectional Population-based Study 168

3. Comparable Effectiveness of 45- and 20-minute Post-infusion Scalp Cooling Time in Preventing Paclitaxel-induced Alopecia – A Randomized Controlled Trial 170

4. Burdens and Evolving Management of Hair Loss: Expert Review 171

5. Central Centrifugal Cicatricial Alopecia not Linked to Comorbidities 174

6. Characterizing the Willingness to Undergo Treatment in Patients with Alopecia Areata 175

7. Assessment of Health-related Quality of Life in Patients with Frontal Fibrosing Alopecia 177

8. Study Investigating Oral JAK Inhibitor for Alopecia Areata Meets Endpoint 178

9. Periodontitis Associated with Risk for Alopecia Areata 180

10. Platelet-rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-analysis and Meta-regression Study 181

11. Food and Drug Administration to Review Ritlecitinib for Alopecia Areata 182

12. Reliability Assessment of Alopecia-related Most-viewed Videos on TikTok 184

Section 8: Miscellaneous

1. Specific Features of Amoxicillin-associated Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Nationwide Study 186

2. The Relationship between Erythema Nodosum and Prognosis in Systemic Sarcoidosis: A Retrospective Cohort Study 187

3. Hyaluronic Acid Filler Injection for Localized Scleroderma—Case Report and Review of Literature on Filler Injections for Localized Scleroderma 189

4. Insights in Skin of Color Patients with Atopic Dermatitis and the Role of Skincare in Improving Outcomes 190

5. Lasers for Cutaneous Lesions: An Update 191

6. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial 192

7. Association between Low-dose Methotrexate Exposure and Melanoma: A Systematic Review and Meta-analysis 193

8. Nonlesional Lupus Skin Contributes to Inflammatory Education of Myeloid Cells and Primes for Cutaneous Inflammation 195

9. MAPKinase Inhibition after Failure of Immune Checkpoint Blockade in Patients with Advanced Melanoma – An Evaluation of the Multicenter Prospective Skin Cancer Registry 196

10. Survival and Tumor Characteristics of Patients Presenting with Single Primary versus Second Primary Melanoma Lesions 197

11. Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (SWOG 1512) 198

12. Head-to-head Comparison of 4 Hyaluronic Acid Dermal Fillers for Lip Augmentation: A Multicenter Randomized, Quadruple-blind, Controlled Clinical Trial 200

13. Characterization of Meibomian Gland Dysfunction in Patients with Rosacea 201

14. Open-label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis 203

15. Overall Survival with First-line Atezolizumab in Combination with Vemurafenib and Cobimetinib in $BRAF^{V600}$ Mutation-positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study 204

16. Persistent Rubella Virus in Skin Inflammations 206

17. Cardiovascular Disease Risk in Patients with Pyoderma Gangrenosum 207

18. Factors Associated with Depression, Anxiety and Severe Mental Illness Among Adults with Atopic Eczema or Psoriasis: A Systematic Review and Meta-analysis 209

19. Cost-utility Analysis of Rituximab versus Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris 211

20. Roller Microneedles Transdermal Delivery of Compound Lidocaine Cream for Enhancing the Analgesic Effect: A Randomized Self-controlled Trial 212

21. Clinical Outcomes of high-risk Cutaneous Squamous Cell Carcinomas Treated with Mohs Surgery Alone: An Analysis of Local Recurrence, Regional Nodal Metastases, Progression-free Survival, and Disease-specific Death 214

22. Safety and Efficacy of TGF-β1/1/COX-2 Silencing Therapeutic in Adults with Cutaneous Squamous Cell Carcinoma in Situ 215

23. Efficacy of Dupilumab in Chronic Prurigo and Chronic Idiopathic Pruritus: A Systematic Review of Current Evidence and Analysis of Response Predictors 216

24. Risk of Hematologic Cancer in Patients with Undifferentiated Pruritus 218

25. Correlations between Hormonal Intrauterine Devices and Androgenic Skin Conditions: A Retrospective Cohort Study 219

26. Patch Testing in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Literature Review 221

27. Human Papillomavirus Vaccine in Patients with Palmoplantar Warts 222

28. Home Treatment of Single Cutaneous Warts Combining Face-to-face and Teledermatology Consultation: A New Perspective 223

29. Reduction in Severity of Radiation-induced Dermatitis in Head and Neck Cancer Patients Treated with Topical Aloe Vera Gel: A Randomized Multicenter Double-blind Placebo-controlled Trial 224

30. Skin Microbiome Variation with Cancer Progression in Human Cutaneous Squamous Cell Carcinoma 226

31. Association of Patient Risk Factors, Tumor Characteristics, and Treatment Modality with Poor Outcomes in Primary Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-analysis 227

32. Successful Treatment of Cheilitis Granulomatosa with Certolizumab and Ustekinumab 229

33. Impacts of Sun Protection and Skin Care Habits in the Biophysical and Morphological Properties of Young Men Skin 229

34. Patients with Severe Dermatitis Express Phobia of Topical Corticosteroids 230

35. Biomarkers of Tretinoin Precursors and Tretinoin Efficacy in Patients with Moderate-to-Severe Facial Photodamage: A Randomized Clinical Trial 232

36. Obesity-related SNPs and Weight Gain Following First-line Antiretroviral Therapy 233

37. A Phase II Clinical Trial of Camrelizumab (CAM, an IgG4 Antibody Against PD-1) Combined with Apatinib (APA, a VEGFR-2 Tyrosine Kinase Inhibitor) and Temozolomide (TMZ) as the First-line Treatment for Patients (pts) with Advanced Acral Melanoma (AM) 235

38. Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients with Pemphigus 236

39. Application of Emollient before TCS may be Favorable in Inflammatory Dermatoses 238

40. Are Facial Topical Corticosteroids Linked to Cataracts and Glaucoma? 239

41. Association between Psoriasis and Alopecia Areata: A Systematic Review and Meta-analysis 241

42. Efficacy and Safety of Topical Nitric Oxide—Releasing Berdazimer Gel in Patients with Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial 242

43. Case Series of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis with Nivolumab and Nivolumab/Ipilimumab Combination Therapy in Metastatic Melanoma 243

44. Bullous Pemphigoid: Three Main Clusters Defining Three Outcome Profiles 245

45. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-cell Carcinoma 246

46. Chronic Pruritus in Multiple Sclerosis and Clinical Correlates 247

47. Measuring Asymmetry in Facial Morphea Via 3-dimensional Stereophotogrammetry 248

Index *251*